ALS drug sets the stage for fresh FDA debate; Implosions everywhere you look; Big names turn up at biotechs; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
Interested in mental health? My colleague Nicole DeFeudis is hosting a virtual panel next week on how a new brand of biotech is out to use modified psychedelics to rewire the brain in search of new and better therapies. You can attend at no cost and it promises to be a dynamic conversation. Check it out here.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.